Mga Batayang Estadistika
| CIK | 1447362 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Castle Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 8, 2025 |
AMENDED AND RESTATED BYLAWS OF CASTLE BIOSCIENCES, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CASTLE BIOSCIENCES, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the certificate of incorporation of the corporation (as the same may be amended and/or restated from |
|
| August 4, 2025 |
Exhibit 99.1 Castle Biosciences Reports Second Quarter 2025 Results Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - August 4, 2 |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 4, 2025 |
greement, dated June 20, 2025 by and between the Registrant and Frank Stokes. Exhibit 10.5 C-Suite and SVP Form AMENDED PARTICIPATION AGREEMENT Name: Frank Stokes Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Partic |
|
| August 4, 2025 |
greement, dated June 20, 2025 by and between the Registrant and Kristen Oelschlager. Exhibit 10.7 C-Suite and SVP Form AMENDED PARTICIPATION AGREEMENT Name: Kristen Oelschlager Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this |
|
| August 4, 2025 |
, 2025, by and between the Registrant and Perimeter Gateway Portfolio LLC. Exhibit 10.3 OFFICE LEASE AGREEMENT FOR TWO SCOTTSDALE LANDING PERIMETER GATEWAY PORTFOLIO LLC, a Delaware limited liability company, as Landlord and CASTLE BIOSCIENCES, INC., a Delaware corporation, as Tenant Dated: 05/14/2025, 2025 OFFICE LEASE AGREEMENT THIS OFFICE LEASE AGREEMENT is made and entered into as of the Effective Date by and between PERIMETER GATEWAY PORTFOLIO LLC, a Delaware limite |
|
| August 4, 2025 |
exhibit992q22025 ©2025 Castle Biosciences 1 Empowering people, informing care decisions August 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 4, 2025 |
Non-Employee Director Compensation Policy, as amended effective May 22, 2025. Exhibit 10.4 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 28, 2021 Amended January 24, 2022 Amended: January 31, 2023 Amended: May 31, 2024 Amended: May 22, 2025 (the “Effective Date”) Each member of the Board of Directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) who is a non-employee director of the Company (each such m |
|
| August 4, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 4, 2025 |
greement, dated June 20, 2025 by and between the Registrant and Toby Juvenal. Exhibit 10.6 C-Suite and SVP Form AMENDED PARTICIPATION AGREEMENT Name: Toby Juvenal Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Partic |
|
| May 23, 2025 |
Amended and Restated Certificate of Incorporation of Castle Biosciences, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CASTLE BIOSCIENCES, INC. Derek Maetzold hereby certifies that: ONE: He is the duly elected and acting President and Chief Executive Officer of Castle Biosciences, Inc., a Delaware corporation. TWO: The date of filing of said corporation’s original certificate of incorporation with the Delaware Secretary of State was September 12, 200 |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| May 5, 2025 |
Exhibit 99.1 Castle Biosciences Reports First Quarter 2025 Results Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIEN |
|
| May 5, 2025 |
©2025 Castle Biosciences 1 Empowering people, informing care decisions May 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| May 5, 2025 |
by and between the Registrant and Tannos Land Holdings III, LLC Exhibit 10.2 COMMERCIAL LEASE AMENDMENT USE OF THIS FORM BY PERSONS WHO ARE NOT MEMBERS OF THE TEXAS ASSOCIATION OF REALTORS®, INC. IS NOT AUTHORIZED. ©Texas Association of REALTORS®, Inc. 2022 AMENDMENT TO THE COMMERCIAL LEASE BETWEEN THE UNDERSIGNED PARTIES CONCERNING THE LEASED PREMISES AT 505 S Friendswood Dr 313, Friendswood, TX 77546 Effective on March 7, 2025 , Landlord and Tenant amend the |
|
| May 5, 2025 |
exhibit992q12025earnings ©2025 Castle Biosciences 1 Empowering people, informing care decisions First Quarter 2025 May 5, 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission Fi |
|
| May 5, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of April 4, 2025, by a |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Castle Biosciences, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2019 Equity Incentive Plan, Common Stock, $0.001 per share Other 1,424,159 $26.55 $37,811,42 |
|
| February 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 27, 2025 |
Exhibit 19.1 CASTLE BIOSCIENCES, INC. INSIDER TRADING POLICY INTRODUCTION During the course of your relationship with Castle Biosciences, Inc. (the “Company”), you may receive material information that is not yet publicly available (“material nonpublic information”) about the Company or other publicly traded companies that the Company has business relationships with. Material nonpublic information |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
©2025 Castle Biosciences 1 Empowering people, informing care decisions February 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 27, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 CASTLE BIOSCIENCES, INC. SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation AltheaDx, Inc. Delaware Cernostics, Inc. Delaware Myriad myPath, LLC Delaware Castle Narnia Way Real Estate Holding 1, LLC Texas |
|
| February 27, 2025 |
Exhibit 99.1 Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities of $293 million, a $50 million increase compared |
|
| February 27, 2025 |
©2025 Castle Biosciences 1 Empowering people, informing care decisions Fourth Quarter 2024 February 27, 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2025 |
©2025 Castle Biosciences 1 Empowering people, informing care decisions Preliminary Fourth Quarter and Year-End Results 2024 January 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| January 13, 2025 |
EXHIBIT 99.1 Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results 2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023 Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities expected to be app |
|
| November 14, 2024 |
CSTL / Castle Biosciences, Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SC 13G/A 1 fp0090935-8sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Castle Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 14843C105 (CUSIP |
|
| November 4, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions November 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| November 4, 2024 |
Exhibit 10.01 CONFIRMATION OF AMENDMENT PROVISIONS THIS CONFIRMATION OF AMENDMENT PROVISIONS (the“Agreement”), made and agreed as of the date of the last party to sign below by and between CASTLE BIOSCIENCES, INC. (“Tenant”) and ACA CONCOURSE EAST UNIT 3 LLC (“Landlord”). WITNESSETH: WHEREAS, Landlord and Tenant entered into a certain Lease Agreement dated April 1, 2022 as amended by the First Ame |
|
| November 4, 2024 |
Exhibit 99.1 Castle Biosciences Reports Third Quarter 2024 Results Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Nov. 4, 2024-Castle Biosciences, Inc. (Nasdaq: CSTL), a company impr |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 4, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions Third Quarter 2024 November 4, 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| November 4, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| August 5, 2024 |
©2024 Castle Biosciences 1 Second Quarter 2024 August 5, 2024 Empowering people, Informing care decisions ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 5, 2024 |
Non-Employee Director Compensation Policy, as amended effective May 31, 2024 Exhibit 10.1 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 28, 2021 Amended January 24, 2022 Amended: January 31, 2023 Amended: May 31, 2024 (the “Effective Date”) Each member of the Board of Directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee |
|
| August 5, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions August 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 5, 2024 |
Exhibit 99.1 Castle Biosciences Reports Second Quarter 2024 Results Q2 2024 revenue increased 74% over Q2 2023 to $87 million Q2 2024 total test reports increased 49% over Q2 2023 Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Aug. 5, 2024-Castle Biosciences, Inc. (Nasdaq: CSTL), a company imp |
|
| May 24, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 2, 2024 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is made and entered into as of the date of the last party to sign below (the “Effectiv |
|
| May 2, 2024 |
Exhibit 10.4 APPENDIX A AMENDED PARTICIPATION AGREEMENT Name: Kristen Oelschlager Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Participa |
|
| May 2, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 2, 2024 |
Amended Participation Agreement, dated April 2, 2024, by and between the Company and Derek Maetzold. Exhibit 10.5 APPENDIX A AMENDED PARTICIPATION AGREEMENT Name: Derek Maetzold Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Participation |
|
| May 2, 2024 |
Amended Participation Agreement, dated April 2, 2024, by and between the Company and Frank Stokes. Exhibit 10.6 APPENDIX A AMENDED PARTICIPATION AGREEMENT Name: Franklin Stokes Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Participation |
|
| May 2, 2024 |
Amended Participation Agreement, dated April 1, 2024, by and between the Company and Tobin Juvenal. Exhibit 10.3 APPENDIX A AMENDED PARTICIPATION AGREEMENT Name: Tobin Juvenal Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Participation A |
|
| May 2, 2024 |
©2024 Castle Biosciences 1 First Quarter 2024 May 2, 2024 Empowering people, Informing care decisions ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission Fi |
|
| May 2, 2024 |
Exhibit 99.1 Castle Biosciences Reports First Quarter 2024 Results Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $255-265 million from $235-240 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - May 2, 2024-Castle Biosciences, Inc. (Nasdaq: CSTL), a company impro |
|
| May 2, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions May 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| April 12, 2024 |
CASTLE BIOSCIENCES, INC. 505 S. Friendswood Drive, Suite 401 Friendswood, Texas 77546 CASTLE BIOSCIENCES, INC. 505 S. Friendswood Drive, Suite 401 Friendswood, Texas 77546 April 12, 2024 Division of Corporation Finance Office of Trade & Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Castle Biosciences, Inc. Registration Statement on Form S-3 File No. 333-277470 Ladies and Gentlemen: Castle Biosciences, Inc. (the “Registrant”) |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| March 27, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the E |
|
| February 28, 2024 |
Exhibit 99.1 Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment securities of $243 million Two critical peer-reviewed publi |
|
| February 28, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 CASTLE BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CASTLE BIOSCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and |
|
| February 28, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 CASTLE BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CASTLE BIOSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and |
|
| February 28, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 CASTLE BIOSCIENCES, INC. SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation AltheaDx, Inc. Delaware Cernostics, Inc. Delaware Myriad myPath, LLC Delaware Castle Narnia Way Real Estate Holding 1, LLC Texas |
|
| February 28, 2024 |
Amendment to Purchase Sale Agreement of Land, dated Exhibit 10.38 Execution Version SECOND AMENDMENT TO COMMERCIAL CONTRACT - UNIMPROVED PROPERTY THIS SECOND AMENDMENT TO COMMERCIAL CONTRACT - UNIMPROVED PROPERTY (this “Second Amendment”) is made and entered into as of January 9, 2024 (the “Effective Date”) by and between HAL B. BOONE, an individual residing in Friendswood, Texas (the “Seller”) and CASTLE BIOSCIENCES, INC., a Delaware corporation, |
|
| February 28, 2024 |
Exhibit 10.20 Castle Biosciences, Inc. SEVERANCE AND CHANGE IN CONTROL PLAN EFFECTIVE DATE: November 3, 2023 Section 1. INTRODUCTION. The purpose of this Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”) is to provide for severance and/or Change in Control (as defined below) benefits to eligible employees of the Company under circumstances described in the Plan. The Plan f |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 S-8 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
Exhibit 4.3 CASTLE BIOSCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| February 28, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions February 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Castle Biosciences, Inc. |
|
| February 28, 2024 |
©2024 Castle Biosciences 1 Fourth Quarter 2023 February 28, 2024 Empowering people, Informing care decisions ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
Castle Biosciences, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 Castle Biosciences, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Castle Biosciences, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy |
|
| February 28, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.6 CASTLE BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF 1 CASTLE BIOSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existi |
|
| February 28, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 14, 2024 |
CSTL / Castle Biosciences, Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SC 13G 1 fp0086874-12sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* Castle Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 14843C105 (CUSIP N |
|
| February 13, 2024 |
CSTL / Castle Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0550-castlebiosciencesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Castle Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 14843C105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to d |
|
| January 8, 2024 |
January 8, 2024 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| January 8, 2024 |
EXHIBIT 99.1 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022 Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment securities expected to be approximately $243 million FRIENDSWOOD, |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissio |
|
| December 4, 2023 |
Castle Biosciences, Inc. 2022 Inducement Plan Exhibit 99.1 Castle Biosciences, Inc. 2022 Inducement Plan Adopted by the Compensation Committee: December 22, 2022 Amended and Restated by the Compensation Committee: November 3, 2023 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)( |
|
| December 4, 2023 |
As filed with the Securities and Exchange Commission on December 4, 2023 As filed with the Securities and Exchange Commission on December 4, 2023 Registration No. |
|
| December 4, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2023 |
, 2023, by and between the Registrant and Alturas Siete I, LLC. Exhibit 10.2 SIXTH AMENDMENT TO STANDARD OFFICE LEASE THIS SIXTH AMENDMENT TO STANDARD OFFICE LEASE (this “Sixth Amendment”) is dated August 2, 2023 (the “Amendment Date”), and made by ALTURAS SIETE I, LLC, an Idaho limited liability company (“Landlord”), and Castle Biosciences, Inc., a Delaware corporation (“Tenant”), and amends that certain Standard Office Lease dated October 5, 2015 (the “Origi |
|
| November 2, 2023 |
Exhibit 99.1 Castle Biosciences Reports Third Quarter 2023 Results Q3 2023 revenue increased 66% over Q3 2022 to $61 million Q3 2023 total test reports increased 52% over Q3 2022 Raising full year 2023 revenue guidance to at least $200 million from at least $180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Nov. 2, 2023-Castle Biosciences, Inc. (Nasdaq: CSTL), a co |
|
| November 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2023 |
Exhibit 10.1 COMMERCIAL CONTRACT - UNIMPROVED PROPERTY USE OF THIS FORM BY PERSONS WHO ARE NOT MEMBERS OF THE TEXAS ASSOCIATION OF REALTORS®, INC. IS NOT AUTHORIZED. ©Texas Association of REALTORS®, Inc. 2022 1.PARTIES: Seller agrees to sell and convey to Buyer the Property described in Paragraph 2. Buyer agrees to buy the Property from Seller for the sales price stated in Paragraph 3. The parties |
|
| November 2, 2023 |
, 2023, by and between the Registrant and Hal B. Boone. Exhibit 10.3 FIRST AMENDMENT TO COMMERCIAL CONTRACT- UNIMPROVED PROPERTY THIS FIRST AMENDMENT TO COMMERCIAL CONTRACT- UNIMPROVED PROPERTY (this “First Amendment”) is made and entered into as of October 4, 2023 (the “Effective Date”) by and between HAL B. BOONE, an individual residing in Friendswood, Texas (the “Seller”) and CASTLE BIOSCIENCES, INC., a Delaware corporation, or its assigns (the “Buy |
|
| November 2, 2023 |
November 2023 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 2, 2023 |
exhibit992q223 August 2023 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 2, 2023 |
Exhibit 99.1 Castle Biosciences Reports Second Quarter 2023 Results Q2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue guidance to at least $180 million from $170-180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Aug. 2, 2023-Castle Biosciences, Inc. (Nasdaq: CSTL), a compan |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 3, 2023 |
Exhibit 99.1 Castle Biosciences Reports First Quarter 2023 Results Q1 2023 revenue increased 57% over Q1 2022 to $42 million Q1 2023 total test reports increased 73% over Q1 2022 Reaffirming full-year 2023 revenue is expected to be between $170-180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas- May 3, 2023-Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving |
|
| May 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission Fi |
|
| May 3, 2023 |
Exhibit 10.4 FOURTH AMENDMENT TO STANDARD OFFICE LEASE (SIETE II - 3707 North 7th Street, Phoenix, Arizona 85014) THIS FOURTH AMENDMENT TO STANDARD OFFICE LEASE (this “Fourth Amendment”) is dated 4/18/2023 (the “Amendment Date”), and made by ALTURAS SIETE II, LLC, an Idaho limited liability company (“Landlord”), and CASTLE BIOSCIENCES, INC., a Delaware corporation (“Tenant”), and amends that certa |
|
| May 3, 2023 |
exhibit992q123 First Quarter 2023 May 3, 2023 Transforming Disease Management 2 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| April 12, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| April 12, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| March 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| March 1, 2023 |
Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Exhibit 99.3 Standard Form CASTLE BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2022 INDUCEMENT PLAN) Castle Biosciences, Inc. (the “Company”), pursuant to its 2022 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock O |
|
| March 1, 2023 |
Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Exhibit 99.2 CASTLE BIOSCIENCES, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2022 INDUCEMENT PLAN) Castle Biosciences, Inc. (the “Company”), pursuant to its 2022 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the term |
|
| March 1, 2023 |
Castle Biosciences, Inc. 2022 Inducement Plan. Exhibit 99.1 CASTLE BIOSCIENCES, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE COMPENSATION COMMITTEE: DECEMBER 22, 2022 1.GENERAL. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq |
|
| February 28, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 CASTLE BIOSCIENCES, INC. SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation AltheaDx, Inc. Delaware Cernostics, Inc. Delaware Myriad myPath, LLC Delaware |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| February 28, 2023 |
Castle Biosciences, Inc. 2022 Inducement Plan. Exhibit 10.11 CASTLE BIOSCIENCES, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE COMPENSATION COMMITTEE: DECEMBER 22, 2022 1.GENERAL. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq |
|
| February 28, 2023 |
exhibit992q422 Fourth Quarter 2022 February 28, 2023 Transforming Disease Management 2 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 28, 2023 |
Exhibit 10.25 FIFTH AMENDMENT TO STANDARD OFFICE LEASE THIS FIFTH AMENDMENT TO STANDARD OFFICE LEASE (this “Fifth Amendment”) is dated 10/24/2022 (the “Amendment Date”), and made by ALTURAS SIETE I, LLC, an Idaho limited liability company (“Landlord”), and CASTLE BIOSCIENCES, INC., a Delaware corporation (“Tenant”), and amends that certain Standard Office Lease dated October 5, 2015 (the “Original |
|
| February 28, 2023 |
Exhibit 10.13 Standard Form CASTLE BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2022 INDUCEMENT PLAN) Castle Biosciences, Inc. (the “Company”), pursuant to its 2022 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock |
|
| February 28, 2023 |
Exhibit 99.1 Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results Full-year 2022 revenue was up 46% over 2021 to $137 million, meeting top end of guided range Delivered 44,419 total test reports in 2022, an increase of 58% compared to 2021 Full-year 2023 revenue is expected to be between $170-180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas- Feb. 28, |
|
| February 28, 2023 |
Exhibit 10.32 COMMERCIAL LEASE AMENDMENT USE OF THIS FORM BY PERSONS WHO ARE NOT MEMBERS OF THE TEXAS ASSOCIATION OF REALTORS®, INC. IS NOT AUTHORIZED. ©Texas Association of REALTORS®, Inc. 2022 AMENDMENT TO THE COMMERCIAL LEASE BETWEEN THE UNDERSIGNED PARTIES CONCERNING THE LEASED PREMISES AT 505 S Friendswood Dr 313, Friendswood, TX 77546 Effective on 1-1-2023 , Landlord and Tenant amend the abo |
|
| February 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| February 28, 2023 |
Castle Biosciences, Inc. Retirement Policy Approved January 13, 2023 Exhibit 10.16 CASTLE BIOSCIENCES, INC. RETIREMENT POLICY EFFECTIVE DATE: JANUARY 15, 2023 Section 1. INTRODUCTION. The purpose of this Castle Biosciences, Inc. Retirement Policy (the “Policy”) is to provide for certain Retirement (as defined below) and retention benefits to eligible employees of the Company under circumstances described in the Policy. The Policy first became effective on the Effec |
|
| February 28, 2023 |
Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Exhibit 10.12 CASTLE BIOSCIENCES, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2022 INDUCEMENT PLAN) Castle Biosciences, Inc. (the “Company”), pursuant to its 2022 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the ter |
|
| February 28, 2023 |
Exhibit 10.14 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 28, 2021 Amended January 24, 2022 Amended: January 31, 2023 (the “Effective Date”) Each member of the Board of Directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will rece |
|
| February 28, 2023 |
Exhibit 10.29 THIRD AMENDMENT TO STANDARD OFFICE LEASE THIS THIRD AMENDMENT TO STANDARD OFFICE LEASE (this “Third Amendment”) is dated February 9, 2023 (the “Amendment Date”), and made by ALTURAS SIETE II, LLC, an Idaho limited liability company (“Landlord”), and CASTLE BIOSCIENCES, INC., a Delaware corporation (“Tenant”), and amends that certain Standard Office Lease dated December 16, 2019 (the |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 9, 2023 |
CSTL / Castle Biosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Castle Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 14843C105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| January 9, 2023 |
EX-99.1 2 cstlprelimresultsq42022.htm EX-99.1 EXHIBIT 99.1 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results 2022 total revenue expected to meet or exceed top end of guided range of $132–137 million Delivered 44,338 total test reports in 2022, an increase of 58% compared to 2021 Growth of 37% year over year in DecisionDx®-Melanoma test report volume Year-end 2022 c |
|
| January 9, 2023 |
January 9, 2023 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissio |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2022 |
Castle Biosciences Announces Third Quarter 2022 Results Q3 2022 revenue grew by 58% over Q3 2021 to $37. |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2022 |
castlebiosciencesq32022v November 2, 2022 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| November 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| August 8, 2022 |
A u g u s t 8 , 2 0 2 2 Tra n s fo r m i n g D i s e a s e M a n a g e m e nt D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 8, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 8, 2022 |
Castle Biosciences Reports Second Quarter 2022 Results Q2 2022 revenue increased 53% over Q2 2021 to $34. |
|
| June 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| June 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Castle Biosciences, Inc. |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 3, 2022 |
CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EXHIBIT 99.1 CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information was prepared to give effect to the transaction between Castle Biosciences, Inc. (?Castle? or the ?Company?) and Cernostics, Inc. (?Cernostics?) pursuant to an Agreement and Plan of Merger dated October 18, 2021, as amended (th |
|
| June 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2022 |
M ay 9 , 2 0 2 2 Tra n s fo r m i n g D i s e a s e M a n a ge m e nt D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2022 |
EXHIBIT 10.3 LEASE AGREEMENT Between ACA CONCOURSE EAST UNIT 3 LLC and CASTLE BIOSCIENCES, INC. Unit 3, Nova Place Concourse, Pittsburgh, Pennsylvania Contents Article I - Premises and Term 1 Section 1.1 - Description of Premises 1 Section 1.2 - Interests Granted With the Premises. 2 Section 1.3 - Term 2 Section 1.4 - Reserved Rights 3 Section 1.5 - Extension Option 3 Article II - Rent 4 Section 2 |
|
| May 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 9, 2022 |
Exhibit 99.1 Castle Biosciences Reports First Quarter 2022 Results Q1 2022 revenue increased 18% over Q1 2021 to $26.9 million Q1 2022 adjusted revenue increased 50% over Q1 2021 to $26.3 million Delivered 8,627 total test reports in Q1 2022, an increase of 68% compared to Q1 2021 DecisionDx-Melanoma test report volume increased 48% over Q1 2021 Conference call and webcast today at 4:30 p.m. ET FR |
|
| May 2, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 21, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 7, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission |
|
| April 4, 2022 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version AGREEMENT AND PLAN OF MERGER by and among Castle Biosciences, inc., a Delaware corporation, Acorn Merger Sub, Inc., a Delaware corporation, AltheaDx, Inc., a Delaware |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2022 |
Exhibit 10.1 FOURTH AMENDMENT TO STANDARD OFFICE LEASE THIS FOURTH AMENDMENT TO STANDARD OFFICE LEASE (this ?Fourth Amendment?) is dated 3/11/2022 (the ?Amendment Date?), and made by ALTURAS SIETE I, LLC, an Idaho limited liability company (?Landlord?), and CASTLE BIOSCIENCES, INC., a Delaware corporation (?Tenant?), and amends that certain Standard Office Lease dated October 5, 2015 (the ?Origina |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| February 28, 2022 |
F e b r u a r y 2 8 , 2 0 2 2 Tra n s fo r m i n g D i s e a s e M a n a ge m e nt D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| February 28, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| February 28, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 CASTLE BIOSCIENCES, INC. SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation Myriad myPath, LLC Delaware Cernostics, Inc. Delaware |
|
| February 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 28, 2022 |
Non-Employee Director Compensation Policy, as amended effective January Exhibit 10.11 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 24, 2022 (the ?Effective Date?) Each member of the Board of Directors (the ?Board?) of Castle Biosciences, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee |
|
| February 28, 2022 |
Exhibit 99.1 Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results Full-year 2021 revenue was up 50% over 2020 to $94.1 million, beating expectations Growth of 55% year over year in total GEP testing volume Full-year 2022 revenue is expected to be between $115-120 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas- Feb. 28, 2022-Castle Biosciences, Inc. (Na |
|
| February 11, 2022 |
CSTL / Castle Biosciences Inc / MAETZOLD DEREK J - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CASTLE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 14843C105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| January 14, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of inco |
|
| January 14, 2022 |
EXHIBIT 99.1 CERNOSTICS, INC. Consolidated Financial Statements for the Nine Months Ended September 30, 2021 (Unaudited) and for the Year Ended December 31, 2020 (Audited) and Independent Accountants? Report CERNOSTICS, INC. TABLE OF CONTENTS Page Independent Accountants' Review Report 1 Independent Auditors' Report 2 Consolidated Financial Statements for the Nine Months Ended September 30, 2021 ( |
|
| January 14, 2022 |
As filed with the Securities and Exchange Commission on January 14, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 14, 2022 Registration No. |
|
| January 14, 2022 |
CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EXHIBIT 99.2 CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information was prepared to give effect to the transaction between Castle Biosciences, Inc. (?Castle? or the ?Company?) and Cernostics, Inc., Inc. (?Cernostics?) pursuant to an Agreement and Plan of Merger dated October 18, 2021, as amend |
|
| January 10, 2022 |
J a n u a r y 1 0 , 2 0 2 2 Tra n s fo r m i n g Pa t i e nt M a n a ge m e nt D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| January 10, 2022 |
EXHIBIT 99.1 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results 2021 Estimated revenue is expected to meet or exceed top end of guided range of $89-93 million Delivered 28,118 gene expression profile test reports in 2021, an increase of 55% compared to 2020 Year-end 2021 cash and cash equivalents expected to be approximately $330 million FRIENDSWOOD, Texas- Jan. 10, |
|
| January 5, 2022 |
EX-10.2 3 exhibit102-masterserviceag.htm EX-10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXHIBIT 10.2 MASTER SERVICES AGREEMENT This Master Services Agreement ("Agreement") is made and entered into as of 12/29/2021 by and between Cas |
|
| January 5, 2022 |
EMPLOYMENT SEPARATION AGREEMENT EXHIBIT 10.1 EMPLOYMENT SEPARATION AGREEMENT This Separation Agreement (the ?Agreement?) is made and entered into as of 12/29/2021 by Castle Biosciences, Inc. (?Castle?), and Bernhard Spiess (the ?Employee?). WHEREAS, Employee was employed by Castle beginning on or about May 2, 2016 in an at-will employment arrangement; WHEREAS, Employee signed an Employee Proprietary Information Agreement with Ca |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| December 6, 2021 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version AGREEMENT AND PLAN OF MERGER by and among Castle Biosciences, Inc. a Delaware corporation, Space Merger Sub, Inc. a Delaware corporation, Cernostics, Inc., a Delaw |
|
| December 3, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| December 3, 2021 |
Exhibit 10.1 SECOND AMENDMENT TO STANDARD OFFICE LEASE THIS SECOND AMENDMENT TO STANDARD OFFICE LEASE (this ?Second Amendment?) is dated 11/29/2021 (the ?Amendment Date?), and made by ALTURAS SIETE II, LLC, an Idaho limited liability company (?Landlord?), and CASTLE BIOSCIENCES, INC., a Delaware corporation (?Tenant?), and amends that certain Standard Office Lease dated December 16, 2019 (the ?Ori |
|
| December 3, 2021 |
Exhibit 10.2 THIRD AMENDMENT TO STANDARD OFFICE LEASE THIS THIRD AMENDMENT TO STANDARD OFFICE LEASE (this ?Third Amendment?) is dated 11/29/2021 (the ?Amendment Date?), and made by ALTURAS SIETE I, LLC, an Idaho limited liability company (?Landlord?), and CASTLE BIOSCIENCES, INC., a Delaware corporation (?Tenant?), and amends that certain Standard Office Lease dated October 5, 2015 (the ?Original |
|
| November 8, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2021 |
Exhibit 99.1 Castle Biosciences Announces Third Quarter 2021 Results Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $89-93 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas- Nov. 8, 2021-Castle Biosciences, Inc. (Nasdaq: CSTL), a company appl |
|
| November 8, 2021 |
N o v e m b e r 8 , 2 0 2 1 A p p l y i n g i n n o v a t i v e d i a g n o s t i c s t o i n f o r m d i s e a s e m a n a g e m e n t d e c i s i o n s D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| October 19, 2021 |
EX-99.2 3 investorpresentationocto.htm EX-99.2 O c t o b e r 1 9 , 2 0 2 1 C e r n o st i c s A c q u i s i t i o n D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| October 19, 2021 |
Exhibit 99.1 Castle Biosciences to Acquire Cernostics Fuels mid- and long-term growth with TissueCypher? platform enabling GI franchise Acquisition will expand Castle?s estimated U.S. TAM by approximately $1 billion Castle executive management to host conference call and webcast today at 7:30 a.m. ET FRIENDSWOOD, Texas-(BUSINESS WIRE)?Oct. 19, 2021- Castle Biosciences, Inc. (Nasdaq: CSTL), applyin |
|
| September 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| September 9, 2021 |
W e l l s F a r g o 2 0 2 1 H e a l t h c a r e C o n f e r e n c e S e p t e m b e r 9 , 2 0 2 1 Tr a n s f o r m i n g t h e m a n a g e m e n t o f d e r m a t o l o g i c c o n d i t i o n s D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 9, 2021 |
EX-99.1 2 exhibit991q22021earningsre.htm EX-99.1 Exhibit 99.1 Castle Biosciences Announces Second Quarter 2021 Results Q2 2021 revenues of $22.8 million, compared to $12.7 million in Q2 2020 Q2 2021 total dermatology test report volume of 6,539 DecisionDx-Melanoma test reports increased 70%, compared to Q2 2020 Raising 2021 Revenue Guidance to $89-93 million from $80-83 million Conference call and |
|
| August 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 9, 2021 |
A u g u s t 9 , 2 0 2 1 Tr a n s f o r m i n g t h e m a n a g e m e n t o f d e r m a t o l o g i c c a n c e r s a n d o t h e r d e r m a t o l o g i c d i s e a s e s w i t h h i g h u n m e t n e e d D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| August 9, 2021 |
Consulting Agreement, dated May 7, 2021, by and among the Registrant and Joseph C. Cook III Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is made as of May 7, 2021 (the ?Effective Date?) by and between CASTLE BIOSCIENCES, INC., a Delaware corporation (the ?Company?), and JOSEPH C. COOK III, an individual (?Consultant?). The Company desires to benefit from Consultant?s expertise by retaining Consultant as a consultant, and Consultant desires to perform cons |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| June 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| May 10, 2021 |
Exhibit 99.1 Castle Biosciences Announces First Quarter 2021 Results Q1 2021 revenues of $22.8 million, compared to $17.4 million in Q1 2020 Q1 2021 total dermatology test report volume of 4,805 Initiates 2021 Revenue Guidance of $80-83 million Q1 2021 gross margin of 87% Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas- May 10, 2021-Castle Biosciences, Inc. (Nasdaq: CSTL), a d |
|
| May 10, 2021 |
M ay 1 0 , 2 0 2 1 Tr a n s f o r m i n g t h e m a n a g e m e n t o f d e r m a t o l o g i c c a n c e r s a n d o t h e r d e r m a t o l o g i c d i s e a s e s w i t h h i g h u n m e t n e e d D I S C L A I M E RS F O R W A R D - L O O K I N G S T A T E M E N T S The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2021 |
Non-Employee Director Compensation Policy, as amended effective May Exhibit 10.4 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: May 7, 2021 (the ?Effective Date?) Each member of the Board of Directors (the ?Board?) of Castle Biosciences, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee Direc |
|
| May 10, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO STANDARD OFFICE LEASE THIS FIRST AMENDMENT TO STANDARD OFFICE LEASE (this ?Amendment?) is made this 16th day of February, 2021 (the ?Amendment Date?), by ALTURAS SIETE II, LLC, an Idaho limited liability company (?Landlord?), and CASTLE BIOSCIENCES, INC., a Delaware corporation (?Tenant?), and amends that certain Standard Office Lease dated December 16, 2019 (the ?O |
|
| May 10, 2021 |
Exhibit 10.2 CASTLE BIOSCIENCES, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of September 15, 2008 (the ?Effective Date?) by and between Castle Biosciences, Inc., a Delaware corporation (the ?Company?), and Kristen Oelschlager (?Executive?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). R E C I |
|
| May 10, 2021 |
Exhibit 10.3 CASTLE BIOSCIENCES, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of October 1, 2008 (the ?Effective Date?) by and between Castle Biosciences, Inc., a Delaware corporation (the ?Company?), and Toby Juvenal (?Executive?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). R E C I T A L S W |
|
| May 10, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 27, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| March 11, 2021 |
Non-Employee Director Compensation Policy, as amended effective January 28, 2021. Exhibit 10.11 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 28, 2021 (the ?Effective Date?) Each member of the Board of Directors (the ?Board?) of Castle Biosciences, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee |
|
| March 11, 2021 |
March 11, 2021 (File No. 333-25 As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 11, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| March 11, 2021 |
Exhibit 10.23 FIRST AMENDMENT TO COMMERCIAL LEASE THIS FIRST AMENDMENT TO COMMERCIAL LEASE (this ?Amendment?) is entered into between TANNOS LAND HOLDINGS III, LLC, a Texas limited liability company (?Landlord?), and CASTLE BIOSCIENCE, INC., a Delaware corporation (?Tenant?), with reference to the following: A.Landlord and Tenant entered into that certain Commercial Lease dated December 17, 2019 ( |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| March 8, 2021 |
Exhibit 99.1 Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results Full-year 2020 revenues of $62.6 million, up 21% compared to 2019 Full-year 2020 dermatology test report volume up 8% compared to 2019 Full-year 2020 gross margin of 85% Earlier today, the Company launched Integrated DecisionDx-Melanoma Test Result, Utilizing AI to Predict Individualized Risk Conference call and we |
|
| March 8, 2021 |
EX-99.2 3 cstlq42020investorpresen.htm EX-99.2 M a r c h 8 , 2 0 2 1 Tra n s fo r m i n g t h e m a n a ge me nt o f d e r mato l o g i c c a n c e rs D I S C L A I M E RS F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) CASTLE BIOSCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 14843C 105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) CASTLE BIOSCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 14843C 105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 17, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common sto |
|
| February 16, 2021 |
EX-99.1 2 d132358dex991.htm EX-99.1 EXHIBIT 99.1 – JOINT FILING AGREEMENT JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing with the other reporting person of a statement on Schedule 13G (including amendments thereto) with respect to the common stock, $0.001 par value of Castle |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No. 1 Castle Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 14843C105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1) * Castle Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 14843C 10 5 (CUSIP Number) D |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2021 |
Exhibit 99.1 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results Delivered 18,185 gene expression profile test reports in 2020 Year-end 2020 cash and cash equivalents were approximately $410 million Final, expanded LCD for CMS coverage for DecisionDx-Melanoma test became effective on Dec. 6, 2020 Launched two new skin cancer tests in 2H2020, increasing estimated in-m |
|
| January 13, 2021 |
castleslidepresentationj The Skin Cancer Diagnostics Company January 2021 NASDAQ: CSTL COMPANY PRESENTATION 2 DISCLAIMERS › Forward-Looking Statements › The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| December 22, 2020 |
Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2020 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| December 16, 2020 |
CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-251331 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.001 per share 4,600,000(1) $58.00 $266,800,000 $29,108 (1) Includes share |
|
| December 16, 2020 |
Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock Exhibit 99.1 Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock FRIENDSWOOD, Texas – Dec. 14, 2020 – Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell $125,000,000 of shares of its common stock. In connection with the offering, Castle ex |
|
| December 16, 2020 |
Exhibit 1.1 Execution Version CASTLE BIOSCIENCES, INC. (a Delaware corporation) 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENT December 15, 2020 SVB Leerink LLC Robert W. Baird & Co. Incorporated as Representatives of the several Underwriters c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 c/o Robert W. Baird & Co. Incorporated 777 East Wisconsin Avenue Milw |
|
| December 16, 2020 |
Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock Exhibit 99.2 Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock FRIENDSWOOD, Texas – Dec. 15, 2020 – Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds to Castle from the offering, before deducting underwrit |
|
| December 16, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 Castle Biosciences Inc (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissio |
|
| December 14, 2020 |
Youâve Exceeded the SECâs Traffic Limit EXHIBIT 4.10 CASTLE BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20 CASTLE BIOSCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between CASTLE BIOSCIENCES, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized an |
|
| December 14, 2020 |
Youâve Exceeded the SECâs Traffic Limit EXHIBIT 4.9 CASTLE BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 CASTLE BIOSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between CASTLE BIOSCIENCES, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and |
|
| December 14, 2020 |
Youâve Exceeded the SECâs Traffic Limit EXHIBIT 4.5 CASTLE BIOSCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Se |
|
| December 14, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2020 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| December 14, 2020 |
castlepresentationfiledd The Skin Cancer Diagnostics Company November 9, 2020 NASDAQ: CSTL COMPANY PRESENTATION 2 DISCLAIMERS › Forward-Looking Statements › The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| December 14, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 14, 2020 Registration No. |
|
| December 14, 2020 |
SUBJECT TO COMPLETION, DATED DECEMBER 14, 2020 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| December 14, 2020 |
Youâve Exceeded the SECâs Traffic Limit EXHIBIT 4.8 CASTLE BIOSCENCES, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 CASTLE BIOSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between CASTLE BIOSCIENCES, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing |
|
| November 9, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 9, 2020 |
EXHIBIT 10.1 Castle Biosciences, Inc. Restricted Stock Unit Grant Notice (2019 Equity Incentive Plan) Castle Biosciences, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all |
